Abstract 2489: HER2 peptide-specific immunogenicity correlates with pathologic response following HER2-pulsed dendritic cell vaccination for early breast cancer

Introduction: We have developed an autologous HER2-pulsed dendritic cell (DC) vaccine that induces robust T-cell responses in early breast cancer. We have also previously demonstrated anti-HER2 Th1 responses to select class II peptides are preferentially lost early in HER2pos breast tumorigenesis. W...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2015-08, Vol.75 (15_Supplement), p.2489-2489
Main Authors: Fracol, Megan E., Datta, Jashodeep, Xu, Shuwen, Lowenfeld, Lea, Fitzpatrick, Elizabeth, Mies, Carolyn, Zhang, Paul J.L., Roses, Robert E., Fisher, Carla, Czerniecki, Brian J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: We have developed an autologous HER2-pulsed dendritic cell (DC) vaccine that induces robust T-cell responses in early breast cancer. We have also previously demonstrated anti-HER2 Th1 responses to select class II peptides are preferentially lost early in HER2pos breast tumorigenesis. We aimed to compare peptide-specific Th1 responses between pathologic complete (pCR) and incomplete responders (
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2015-2489